Akorn buys Hi-Tech Pharmacal for USD640m
M2 - 30 mins ago
Pharmaceutical company Akorn (NasdaqGS:AKRX) disclosed on Thursday the completion of the acquisition of Hi-Tech Pharmacal Co (NasdaqGS:HITK) for a purchase price of USD640m in cash.
Actavis to purchase four products from Akorn
M2 - 1 hr 41 mins ago
Pharmaceutical company Actavis (NYSE:ACT) reported on Thursday the launch of agreements to acquire four currently marketed products and one product under development from Akorn and Hi-Tech Pharmacal Co.
Akorn Completes Acquisition of Hi-Tech Pharmacal
Business Wire - Thu Apr 17, 8:20AM CDT
Akorn, Inc. (NASDAQ: AKRX), a niche pharmaceutical company, announced today that it has completed its previously announced acquisition of Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) for $640 million in cash. The combination of Akorn and Hi-Tech will transform the Company into a larger, more diversified generic player. This combination also brings critical mass and scale to Akorn's business and strengthens the Company's position with retail and institutional customers.
Repligen Corporation Set to Join the S&P SmallCap 600
PR Newswire - Tue Apr 15, 4:53PM CDT
Repligen Corporation (NASD:RGEN) will replace Hi-Tech Pharmacal Co., Inc. (NASD:HITK) in the S&P SmallCap 600 after the close of trading on Thursday, April 17. S&P SmallCap 600 constituent Akorn Inc. (NASD:AKRX) is acquiring Hi-Tech Pharmacal Co. in a deal expected to be completed soon.
Akorn Receives FTC Clearance for Hi-Tech Pharmacal Acquisition
Business Wire - Mon Apr 14, 6:00PM CDT
Akorn, Inc. (NASDAQ: AKRX) today announced that the U.S. Federal Trade Commission (FTC) has voted to approve Akorn's acquisition of Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK). The unanimous vote in support of the transactions follows Akorn's agreement to a proposed consent order requiring divestiture of certain products as a condition to obtaining FTC approval. The parties have now obtained all regulatory approvals required to consummate the acquisition, and intend to close by the end of this week.
Hi-Tech Pharmacal Up 28.3% Since SmarTrend Uptrend Call (HITK)
Comtex SmarTrend(R) - Fri Apr 11, 4:57PM CDT
SmarTrend identified an Uptrend for Hi-Tech Pharmacal (NASDAQ:HITK) on June 19th, 2013 at $33.77. In approximately 10 months, Hi-Tech Pharmacal has returned 28.34% as of today's recent price of $43.34.
Shares of HITK Up 28.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 04, 11:07AM CDT
SmarTrend identified an Uptrend for Hi-Tech Pharmacal (NASDAQ:HITK) on June 19th, 2013 at $33.77. In approximately 10 months, Hi-Tech Pharmacal has returned 28.43% as of today's recent price of $43.37.
Hi-Tech Pharmacal Reports Sales of $59.9 Million for the Third Quarter Ended January 31, 2014
Business Wire - Tue Mar 11, 6:00AM CDT
Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) today reported results for the third fiscal quarter ended January 31, 2014.
Hi-Tech Pharmacal Has Returned 28.2% Since SmarTrend Recommendation (HITK)
Comtex SmarTrend(R) - Thu Mar 06, 11:06AM CST
SmarTrend identified an Uptrend for Hi-Tech Pharmacal (NASDAQ:HITK) on June 19th, 2013 at $33.77. In approximately 9 months, Hi-Tech Pharmacal has returned 28.22% as of today's recent price of $43.30.
Akorn Guidance Worries Street As Strategy Hits Delays
at Investor's Business Daily - Mon Mar 03, 4:30PM CST
Specialty drugmaker Akorn's Q4 earnings met estimates Monday, but its 2014 guidance and a new accounting problem halted the IBD 50 stock dead in its tracks. Akorn (AKRX) said profit totaled 14 cents a share, up a penny from the year-earlier quarter...
Akorn Q4 Meets But Guidance Disappoints, Stock Down
at Investor's Business Daily - Mon Mar 03, 9:07AM CST
Specialty drugmaker Akorn (AKRX) Monday reported a Q4 in line with estimates, but it guided 2014 below expectations and shares plummeted 15% in early trading in the stock market today. The company said profit totaled 14 cents a share, up a penny from...
Hi-Tech Pharmacal Shares Up 28.4% Since SmarTrend's Buy Recommendation (HITK)
Comtex SmarTrend(R) - Thu Feb 27, 9:43AM CST
SmarTrend identified an Uptrend for Hi-Tech Pharmacal (NASDAQ:HITK) on June 19th, 2013 at $33.77. In approximately 8 months, Hi-Tech Pharmacal has returned 28.40% as of today's recent price of $43.36.
Youngevity International (YGYI) Inks Consulting Agreement with Creative Memories Co-Founder Rhonda Kanning Anderson
Business Wire - Wed Feb 26, 7:05AM CST
Youngevity International, Inc. (OTCQX: YGYI) (www.YGYI.com), a global direct marketer of nutritional and lifestyle products and also a vertically-integrated producer of gourmet coffees for the commercial, retail and direct sales channels, announced today that Rhonda Kanning Anderson will immediately begin advising the company on expanding its product offering in Scrap Books, Photo Albums, and Memory Books in both the digital and paper formats. Rhonda will have a keen focus on helping build the Heritage Makers Brand in the area of digital scrap booking as well as assist in the development and marketing of more traditionally oriented products for this space.
Actavis, Valeant, Jazz: New Roles For Specialty Pharma
at Investor's Business Daily - Fri Feb 07, 1:12PM CST
Last month, during an otherwise ho-hum conference call on 2014 financial guidance, Valeant Pharmaceuticals CEO Michael Pearson electrified the stock market by making an audacious promise. "Today we're introducing our sixth strategic initiative, which...